Vivos Inc (QB) (RDGL) ニュース

I always knew that when ASCM shows up, the volume gets as lively as a barn dance, making it way easier to trade the stock

Dude, this here's some awesome info. Can ya school me a bit? Where do y'all find them MM breakdowns in share volume

Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.

One week is enough.-

June 29th 2024.....

https://tradersque.com/vivos-inc-announces-ide-submission-for-radiogel/

March 27th 2024.....

https://tradersque.com/vivos-inc-innovation-in-precision-radionuclide-therapy/

https://isopet.com/

Exciting update on the horizon for $RDGL in the coming weeks!

🌟 Stay tuned, for our coverage following any major updates.

Our previous coverage reached nearly 60,000 readers, highlighting key insights and opportunities. #VivosIncUSA #RadioGel #IsoPet https://t.co/Y0lnknDSBM— TradersQue (@QueTraders) October 6, 2024

It's very possible the sprint meetings will be completed this week imo. Maybe a week or so after that to get the IDE submitted. We are very close.

The Mayo clinic will be starting clinical trials once that IDE is approved.
Exciting times for the company and its shareholders and for cancer patients receiving this treatment.

Less than 2 weeks until the re submission ,,, and due to the 5 sprint discussions, I believe imo that there is a high likelihood of an FDA approval of the IDE.

Then why did MK abandon the pre-sub program, submit a defective IDE he had to withdraw, only to return to the pre-sub program? Occam says incompetence.

current pps meaningless at this anemic volume. Gotta keep it real. What is MK hiding from the market this time? What are the major issues FDA flagged? What is the timetable? Certainly not the timetable he announced 3 1/2 years ago to submit IDE no later than Sept. 21, 2021. The guy both dishonest and incompetent.

That is nice, but the share price tripled due to the announcement of the IDE submission in June of this year.

ASCM has contributed to 7.55% of this years volume at 18,569,582 shares traded through September 30th.....


Side Note: ASCM did not become a active Market Maker participant in RDGL in 2024 until April. From April 1st through September 30th, when ASCM became an active participant, ASCM's percentage of RDGL's trading activity was 8.75%

OTCN has contributed to 5.53% of this years volume at 13,611,278 shares traded through September 30th.....

GTSM has contributed to 31.5% of this years volume at 77,578,211 shares traded through September 30th.....

GTSM numbers later....

Dr. Korenko and RDGL management. Are you paying attention.....

One other interesting fact. RDGL PPS has more than doubled since ASCM's arrival in April where the stock began the month trading at 0.072. At one point since ASCM's arrival the stock even more than tripled to 0.255

We shouldn't have to imagine. An IDE update should be coming this or next week.

I think they will submit before the end of this month.

RDGL trading volume for the first 10 months of 2024 (January 2nd through September 30th) has surpassed the entire year of 2023's volume by 118,017,159. RDGL trading volume for the year of 2023 was 128,083,096.....RDGL trading volume for the first 10 months of 2024 (January 2nd through September 30th) has been 246,100,255.....ASCM did not participate as a RDGL Market Maker the first 3 months of this year. ASCM showed up in April. RDGL trading volume beginning April 1st through September 30th has been 212,295,804. Market Maker ASCM has contributed to 18,569,582 of that volume or 8.745%. Oddly enough ASCM has been consistently been top BID top ASK during much of that time frame.

I can’t imagine there will be any more delays after 5 meetings with the FDA, the only question is how long it will take to resubmit after the final meeting.

What we do know is a monthly update is coming soon enough imo lol

I don’t know whether to believe you or not. Your “ our time has arrived” posts are always wrong. Been over a year since you posted our time was last summer. I want it to be true. I need it to be true. Yet, you have been wrong many times before. Makes me believe you want it run a little to sell and maybe buy back lower, rinse and repeat.

When a company says "SOON" in a PR and nothing happens for weeks and weeks, that's what really pisses me off.

So far RDGL hasn't done that. At least in the short time that I've been here. lol

So around another 500,000 since September 4th.....nice

Currently around 6.5

As soon as tomorrow.
As soon as next week.
As soon as next year.
As soon as last week. 😳

We are all guilty of using" soon" as a time frame. It pretty much means we haven't a clue but know its going to happen.


RDGL

wow 7 million !!! how much do you have now

Scary when a chemist doesn't know what SOON is lol ...look out up top we are fueled and ready for liftoff imo SOON ENOUGH

All I know is FDA meetings will be done by next Wednesday at the latest, just 8 more trading days. CEO purchased shares last week so he is feeling confident and so am I.

"SOON" is one of the most common "wiggle" words used on iHub message boards.

I have several other OTC tickers where SOON is the operative term.

Management uses it as do the posters. Unfortunately, nobody seems to know what it means!! LOL

I don’t think people realize how much is going on behind the scenes besides the pre sub meetings and getting ready to resubmit the IDE.

In the past they have been talking to India and a couple of other countries about isopet and radiogel. Not sure if they are still in communication since it has been awhile since anything was mentioned about this.

If I remember correctly I believe they said they will wait until they are farther along with the IDE, now they didn’t specify if that they were waiting on the IDE approval and or full blown approval.

With these pre sub meetings gives them an extremely high chance of approval, my guess 99percent.

Someone on ST said $2.25 on IDE approval ….

We’ll just have to wait and see.
Should be $1.00 - $2.00 at least by then.
$2.25 is certainly realistic.

I agree, stock price will continue moving up, I’ve been buying a few hundred shares a week, trying to get to 7 million.

Well, you said "soon" first....so lets start with you first. Then I'll ask that poster next.

What is "soon" mean to you? I know we are getting close here but what does soon mean.... a month, 2 months, 3? Asking for all that reads this board.


RDGL

Maybe you should be asking this https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175189156 RDGL long. He's been here way way way longer than little ole me lol..... and I like the way he’s talking!

Great call. Only up 300% since.

Expecting a new 5 year high this coming week. Longs your time has arrived. Get your full position early this week. You will be glad you did.

Let’s Go!
RDGL Oct 2024!!!

$RDGL Timeline: The Road to FDA IDE Approval (Human Clinical Trials) .....



JULY 30th through SEPTEMBER 20th
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175125103








Radiogel had multiple sprint meetings in September with the FDA

October 3, 2024
September Update #Vivos #IsoPet #RadioGel #CancerTreatment ##PRnT $RDGL pic.twitter.com/9fS39HVKpk— Vivos Inc. (@VivosIncUSA) October 3, 2024

$RDGL Three Month Trend Higher High's Higher Low's


OCTOBER 2024

Date*********Close***High***Low******Volume

04 Oct 2024 0.1750 0.1765 0.1697***** 233,668
03 Oct 2024 0.1739 0.1800 0.1690***** 599,301
02 Oct 2024 0.1740 0.1750 0.1615***** 881,281
01 Oct 2024 0.1623 0.1649 0.1610***** 168,163


SEPTEMBER 2024

Date*********Close***High***Low*******Volume

30 Sept 2024 0.1636 0.1636 0.1507***** 640,286
27 Sept 2024 0.1575 0.1670 0.1500*** 1,071,430
26 Sept 2024 0.1661 0.1700 0.1526***** 918,640
25 Sept 2024 0.1639 0.1695 0.1555***** 530,842
24 Sept 2024 0.1630 0.1666 0.1529***** 427,225
23 Sept 2024 0.1639 0.1740 0.1608*** 1,174,211
20 Sept 2024 0.1634 0.1678 0.1575***** 645,738
19 Sept 2024 0.1598 0.1645 0.1510***** 506,525
18 Sept 2024 0.1562 0.1622 0.1505*** 1,125,259
17 Sept 2024 0.1553 0.1583 0.1495***** 865,500
16 Sept 2024 0.1540 0.1574 0.1461***** 951,042
13 Sept 2024 0.1455 0.1545 0.1338*** 1,095,701
12 Sept 2024 0.1355 0.1450 0.1331***** 805,270
11 Sept 2024 0.1420 0.1465 0.1386***** 267,709
10 Sept 2024 0.1414 0.1503 0.1300*** 1,553,373
09 Sept 2024 0.1301 0.1420 0.1230*** 1,317,001
06 Sept 2024 0.1230 0.1270 0.1175***** 553,374
05 Sept 2024 0.1210 0.1259 0.1080*** 1,099,808
04 Sept 2024 0.1186 0.1840 0.1030*** 6,309,957>>>>>News of FDA re-submission delay
03 Sept 2024 0.1516 0.1579 0.1339*** 1,112,671


AUGUST 2024

Date*********Close***High***Low******Volume

30 Aug 2024 0.1345 0.1404 0.1285*** 1,133,820
29 Aug 2024 0.1301 0.1395 0.1280***** 511,543
28 Aug 2024 0.1359 0.1395 0.1291***** 778,974
27 Aug 2024 0.1310 0.1370 0.1275*** 2,028,131
26 Aug 2024 0.1334 0.1339 0.1270***** 621,565
23 Aug 2024 0.1279 0.1345 0.1255*** 1,581,204
22 Aug 2024 0.1270 0.1323 0.1198*** 1,340,090
21 Aug 2024 0.1199 0.1199 0.1172***** 259,518
20 Aug 2024 0.1175 0.1195 0.1130***** 339,905
19 Aug 2024 0.1190 0.1190 0.1160***** 199,908
16 Aug 2024 0.1178 0.1178 0.1101***** 719,341
15 Aug 2024 0.1146 0.1180 0.1073*** 2,129,660
14 Aug 2024 0.1097 0.1099 0.1063***** 300,567
13 Aug 2024 0.1095 0.1134 0.0939*** 2,068,907
12 Aug 2024 0.1133 0.1170 0.1005*** 1,811,650
09 Aug 2024 0.1175 0.1189 0.1016***** 859,328
08 Aug 2024 0.1144 0.1175 0.0990*** 2,273,260
07 Aug 2024 0.1123 0.1200 0.1060*** 1,205,512
06 Aug 2024 0.1135 0.1270 0.0975*** 1,852,777
05 Aug 2024 0.1010 0.1050 0.0870*** 1,083,132
02 Aug 2024 0.0950 0.0950 0.0825*** 1,251,207
01 Aug 2024 0.0850 0.0945 0.0805*** 2,338,254

What does that nearly year old PR have to do with anything now? It's been over 3 years now since MK said he'd submit an IDE application and to date he has failed to do so. Withdrawn applications don't count.

Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.

Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness. We are currently working closely with Mayo Clinic for our initial indication for use of Radiogel for delivering “therapeutic radiation to solid metastatic tumors in lymph nodes associated with papillary thyroid cancer, accessible by percutaneous direct needle injection, in patients who are not surgical candidates or have declined surgery, had non-radioiodine avid disease and had limited burden regional nodal disease.” The Breakthrough Device classification will enhance the schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.

The FDA’s Breakthrough Devices program facilitates accelerated development and expedites the review of breakthrough technologies to help patients potentially gain timely access to technologies that can provide more effective treatment options.

Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.

Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness. We are currently working closely with Mayo Clinic for our initial indication for use of Radiogel for delivering “therapeutic radiation to solid metastatic tumors in lymph nodes associated with papillary thyroid cancer, accessible by percutaneous direct needle injection, in patients who are not surgical candidates or have declined surgery, had non-radioiodine avid disease and had limited burden regional nodal disease.” The Breakthrough Device classification will enhance the schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.

The FDA’s Breakthrough Devices program facilitates accelerated development and expedites the review of breakthrough technologies to help patients potentially gain timely access to technologies that can provide more effective treatment options.

STFU ....